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Abstract
After chikungunya virus (CHIKV) transmission was detected in Puerto Rico in May 2014, 
multiple surveillance systems were used to describe epidemiologic trends and CHIKV-associated 
disease. Of 28 327 cases reported via passive surveillance, 6472 were tested for evidence of 
CHIKV infection, and results for 4399 (68%) were positive. Of 250 participants in household 
cluster investigations, 70 (28%) had evidence of recent CHIKV infection. Enhanced surveillance 
for chikungunya at 2 hospitals identified 1566 patients who tested positive for CHIKV, of whom 
10.9% were hospitalized. Enhanced surveillance for fatal cases enabled identification of 31 cases 
in which CHIKV was detected in blood or tissue specimens. All surveillance systems detected a 
peak incidence of chikungunya in September 2014 and continued circulation in 2015. 
Concomitant surveillance for dengue demonstrated low incidence, which had decreased before 
CHIKV was introduced. Multifaceted chikungunya surveillance in Puerto Rico resolved gaps in 
traditional passive surveillance and enabled a holistic description of the spectrum of disease 
associated with CHIKV infection.
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Following the introduction of chikungunya virus (CHIKV) into the Caribbean in late 2013 
[1, 2], multiple challenges to case surveillance were expected throughout the region, 
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including in the United States territory of Puerto Rico. First, although recommendations for 
surveillance had been provided by the Centers for Disease Control and Prevention (CDC) 
and the Panamerican Health Organization in anticipation of CHIKV introduction into the 
Americas [3], surveillance for chikungunya in Puerto Rico was not yet in place, where 
clinical and public awareness of chikungunya was low. Second, laboratory capacity to 
routinely test suspected cases did not exist. Third, although severe and potentially fatal 
manifestations of CHIKV infection [4–7] had been reported to occur most frequently in 
infants and the elderly [8–10], the expected incidence of such manifestations was unclear 
owing to differences in surveillance methods and potential population-specific differences 
(eg, underlying comorbidities, demographic age structure, and genetic predisposition). 
Fourth, multiple acute febrile illnesses (AFIs) are endemic in Puerto Rico, including dengue 
[11], influenza [12], leptospirosis [13], and melioidosis [14], all of which may be 
misdiagnosed as chikungunya and vice versa. Thus, accurate diagnosis of chikungunya was 
needed to enable appropriate and early initiation of clinical management of AFIs. Last, all of 
these challenges were expected to be exacerbated by the anticipated rapid spread and high 
rate of infection (eg, 38%–63% [3, 15]) associated with chikungunya outbreaks. For these 
reasons, a variety of approaches was implemented to monitor the epidemiologic and clinical 
trends of the chikungunya epidemic in Puerto Rico.
PASSIVE CASE SURVEILLANCE
Passive surveillance for infectious diseases occurs when ill individuals seek medical care, a 
clinician diagnoses the case as being due to a suspected etiologic agent, and the case is 
reported to public health authorities either before or after laboratory diagnostic testing is 
performed. The primary goal of such passive surveillance is to monitor epidemiologic trends 
in diseases. In the case of chikungunya, such monitoring was expected to be delayed due to 
overwhelming case counts, as had been reported during prior outbreaks in immunologically 
naive populations [8, 10]. In Puerto Rico, the infrastructure for a passive chikungunya 
surveillance system (PCSS) was already in place, since the Puerto Rico Department of 
Health (PRDH) and the CDC had collaboratively operated the passive dengue surveillance 
system (PDSS) since the 1960s [11]. The epidemiologic trends of dengue have been 
monitored for decades via the PDSS, including detection of recent dengue epidemics in 
2010 [16] and 2012–2013 (PRDH and CDC, unpublished data).
To initiate passive chikungunya surveillance, the existing dengue case investigation form 
(available at: http://www.cdc.gov/dengue/resources/dengueCaseReports/DCIF_English.pdf) 
was modified to specify clinical suspicion of chikungunya. Clinicians reported suspected 
chikungunya cases to the PRDH using the modified surveillance form, and the existing 
PDSS infrastructure was used to transport surveillance forms and serum specimens to the 
PRDH. Laboratory capacity was established at the PRDH for chikungunya diagnostic 
testing, first by reverse transcription–polymerase chain reaction (RT-PCR) [17] with updated 
primers and later by anti-CHIKV immunoglobulin M (IgM) capture (MAC) enzyme-linked 
immunosorbent assay(ELISA) [18]. After substantial increases in the number of reported 
cases of suspected chikungunya, diagnostic testing was prioritized for hospitalized patients 
and residents of municipalities that had not yet identified cases that had positive results of 
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laboratory tests. Only patients reported to both the PDSS and the PCSS were tested for 
evidence of infection with both dengue virus (DENV) and CHIKV.
Suspected travel-associated and locally acquired chikungunya cases were reported via the 
PCSS beginning in January 2014. The first identified chikungunya case with positive results 
of laboratory tests had illness onset on 5 May 2014, did not report recent travel outside of 
Puerto Rico, and was a resident of the San Juan metropolitan area [19]. Soon thereafter, 
additional chikungunya cases were reported from throughout the San Juan metropolitan area 
and subsequently from throughout the island [19]. As case counts increased from hundreds 
to thousands per week (Figure 1A), the laboratory capacity of the PRDH was exceeded, and 
not all reported cases could be tested. An administrative order was issued in mid-September 
stating that only hospitalized cases of suspected chikungunya should be reported via the 
PCSS. Both hospitalized and nonhospitalized cases continued to be reported through 2015, 
and by April several dozen cases, including cases with positive results of laboratory tests, 
were being reported per week. During the first year of the CHIKV transmission, 28 327 
suspected chikungunya cases (8.0 cases per 1000 population) had been reported via the 
PCSS from all 78 municipalities of Puerto Rico (Figure 2). The incidence of reported cases 
of suspected chikungunya was highest in the San Juan and Ponce metropolitan areas. 
Diagnostic testing was performed on 6472 suspected chikungunya cases, of which 4399 
(68%) had positive results of laboratory tests; all tested positive by RT-PCR except 2 cases 
that were positive by MAC ELISA. Because MAC ELISA was not implemented into routine 
diagnostic testing algorithms until relatively late in the epidemic, it is likely that some 
chikungunya cases were misdiagnosed; however, the relative benefit of having this testing 
routinely performed versus the likelihood of detecting false-positive cases (ie, detection of 
anti-CHIKV IgM antibody in individuals who had been recently infected with CHIKV but 
were presenting for care due to AFI of another etiology) is unclear.
Cases of suspected dengue and cases with positive results of laboratory testing that were 
detected by the PDSS were at low levels in mid-2014 following the dengue epidemic of 
2012–2013 (Figure 1A). A peak in suspected dengue cases reported to the PDSS occurred 
concomitantly with the peak of the chikungunya epidemic in 2014; however, the proportion 
of cases with positive results of laboratory testing that were reported to PDSS did not 
increase, suggesting that the peak in reported cases of suspected dengue was attributable to 
chikungunya cases being reported to both the PCSS and the PDSS. During the first year of 
CHIKV circulation, 8142 suspected dengue cases were reported via the PDSS, of which 225 
(2.8%) had positive results of laboratory tests, representing the lowest annual number of 
dengue cases reported to the PDSS in several decades. A total of 2552 cases were reported 
to both the PDSS and the PCSS, of which 916 (35.9%) were tested for evidence of infection 
with both CHIKV and DENV. Of these, 577 (63%) had evidence of infection with CHIKV, 
20 (2.2%) had evidence of infection with DENV, and 1 (0.1%) had evidence of coinfection 
with both CHIKV and DENV, based on results of RT-PCR.
HOUSEHOLD-BASED CLUSTER INVESTIGATIONS
Because underreporting occurs in all passive surveillance systems owing to some ill 
individuals not seeking medical care, lack of clinical suspicion of chikungunya in clinically 
Sharp et al. Page 3
J Infect Dis. Author manuscript; available in PMC 2017 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
apparent cases, and lack of case reporting of clinically suspected cases [20, 21], the PCSS 
was not expected to detect all chikungunya cases in Puerto Rico. To provide a cross-
sectional view of the reasons for underreporting of cases and subsequently attempt to correct 
such deficiencies, household-based cluster investigations were conducted during the first 
weeks of the epidemic [19]. A convenience sample of chikungunya cases with positive 
results of laboratory testing that were reported via the PCSS was contacted, and household 
visits were scheduled within 30 days of illness onset among index case patients. All 
households within a 50-m radius of the index case patients’ households were offered 
participation, which included completing a questionnaire and providing a serum specimen 
for chikungunya diagnostic testing.
A total of 21 cluster investigations were conducted, with 250 individuals from 137 
households participating [19]. Of these, 70 individuals had evidence of current or recent 
CHIKV infection by RT-PCR or MAC ELISA [18], respectively, of whom 58 (83%) 
reported a current or recent AFI. The majority (63%) of recently ill individuals who had 
positive results of laboratory tests had sought care for their illness, and 13% reported having 
been hospitalized. However, few (20%) reported having received a diagnosis of 
chikungunya, and only 2 (8%) had been reported via the PCSS, demonstrating prominent 
underreporting of clinically apparent chikungunya cases. After conducting cross-testing for 
DENV infection, anti-DENV IgM antibody was detected in serum specimens from 12 
household-investigation participants (5%); DENV nucleic acid was not detected in any 
specimens by RT-PCR. Thus, although there was no evidence of concomitant DENV and 
CHIKV circulation, serologic diagnostic test results demonstrated recent circulation of 
DENV.
Although useful in elucidating the reasons for the underreporting of chikungunya cases and 
estimating the ratio of symptomatic to asymptomatic CHIKV infections, limitations of the 
interpretation of the data gathered through household investigations included (1) a lack of 
representativeness, as participants in the cluster investigations tended to be older than 
individuals who were not available when surveys were conducted; and (2) potential changes 
after the initial months of the epidemic in the trends of ill individuals seeking care, clinical 
suspicion of chikungunya, and reporting of suspected cases.
ENHANCED, FACILITY-BASED SURVEILLANCE
The facility-based Sentinel Enhanced Dengue Surveillance System (SEDSS) was established 
in mid-2012 to better elucidate the incidence, etiology, and clinical course of febrile patients 
presenting for care at 2 hospitals in southern Puerto Rico. Rather than relying on clinicians 
to elect to report suspected cases, as occurs during passive surveillance, the SEDSS 
identifies cases by querying all patients for the presence of fever when they register at the 
emergency department. Febrile patients are then offered participation in the SEDSS, and 
those who agree to participate are tested for DENV, influenza virus, and other common 
causes of febrile illness. In April 2014, laboratory diagnostic testing for chikungunya by RT-
PCR and MAC ELISA was added to the SEDSS diagnostic algorithm, and the first 
chikungunya case with positive results of laboratory testing was identified in late May 
(Figure 1B). Case counts began to steadily increase thereafter until nearly 650 chikungunya 
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cases with positive results of laboratory tests were identified in September. Case detection 
steadily decreased thereafter and throughout early 2015. One year after it had been first 
detected, CHIKV was still being detected in patients enrolled in the SEDSS, although at 
comparatively low levels (n = 9 in April 2015). In total, 1566 chikungunya cases with 
positive results of laboratory tests were detected via the SEDSS during the first year 
following introduction of CHIKV, of which 94% tested positive by RT-PCR and 6% tested 
positive by MAC ELISA.
Similar to the patterns of detection of dengue cases observed through passive surveillance, 
the proportion of dengue cases with positive results of laboratory testing detected by the 
SEDSS was declining following the dengue epidemic in 2012–2013. This pattern continued 
during the first year of CHIKV circulation, wherein just 11 dengue cases with positive 
results of laboratory tests were identified. No CHIKV/DENV coinfections were identified by 
the SEDSS.
Whereas most previous studies of hospitalization rates and severe manifestations associated 
with chikungunya were based on passive surveillance, enhanced, facility-based surveillance 
enabled calculation of a more precise denominator by which to measure the frequency of 
hospitalization and potentially life-threatening complications directly or indirectly 
associated with chikungunya. Previously documented complications of CHIKV infection, 
namely bullous skin lesions and encephalitis, were observed in 8 patients (0.5%) and 7 
patients (0.4%) with clinically apparent chikungunya, respectively. Of 171 patients (10.9%) 
with clinically apparent chikungunya who were hospitalized, many (39%) were infants or 
elderly. Common admitting diagnoses were generally associated with dehydration, pain 
management, and/or complications of preexisting conditions (eg, asthma, diabetes, and 
chronic heart disease); 8 patients (0.5%) with chikungunya were admitted to the intensive 
care unit. Two patients (0.1%) died, both of whom were elderly and had multiple 
comorbidities. Because tissue specimens were not available for either case, it is unclear 
whether these fatal cases were associated with exacerbation of preexisting conditions and/or 
whether CHIKV played a role in the fatal outcome.
ENHANCED DETECTION OF FATAL CASES
The Enhanced Fatal AFI Surveillance System (EFASS) has been collaboratively conducted 
by the PRDH, the Institute of Forensic Sciences of Puerto Rico, and the CDC since 2010. 
Owing to documented underreporting of fatal dengue cases [22], the EFASS was established 
to better enumerate the incidence, etiology, and clinical course of fatal cases with dengue-
like illness. Under the EFASS, fatal cases were compiled for which premortem serum 
specimens were collected via passive and enhanced hospital-based surveillance systems and 
postmortem serum and tissue specimens were collected by forensic pathologists during 
autopsy of patients who died following dengue-like illness. During the first 3 years of 
operation of the EFASS, fatal cases of dengue, leptospirosis, and melioidosis were identified 
that would likely not otherwise have been detected [13, 14, 16, 23]. Diagnostic testing for 
CHIKV infection was added to the EFASS diagnostic algorithm in March 2014.
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The first case of suspected fatal chikungunya was identified by forensic pathologists in late 
May 2014 and had positive results of RT-PCR [19]. Over the following 12 months, 31 
CHIKV-associated fatal cases were detected through the EFASS that were positive by RT-
PCR in serum and/or tissue specimens (0.9 cases per 100 000 population per year; Figure 
1C). As 7 fatal cases were reported to the PRDH via passive surveillance, enhanced 
surveillance enabled detection of >3 times more CHIKV-associated fatal cases than passive 
surveillance alone. Of the 31 CHIKV-associated fatal cases identified, 10 (32%) died at 
home, and 6 (19%) had never sought medical care, both circumstances of which would have 
made identification through passive surveillance impossible. No fatal dengue cases were 
detected during the chikungunya epidemic.
Three additional pertinent findings were gleaned through enhanced surveillance for fatal 
cases. First, all but 2 (94%) of the identified CHIKV-associated fatal cases had one or 
multiple underlying comorbidities, most frequently diabetes, obesity, and hypertension. Such 
findings have been previously associated with fatal chikungunya cases [4]. Second, 
postmortem collection of tissue specimens from 25 cases enabled detection of CHIKV 
antigen by immunohistochemistry analysis in 11 cases (44%), of which 8 (32%) showed 
viral antigen in multiple organs. CHIKV antigen was identified most often in mesenchymal 
tissues and cells of the mononuclear-phagocytic system. Third, although most cases had died 
from complications of preexisting conditions and/or coinfection, at least 3 of the fatal cases 
with CHIKV antigen detected in tissue specimens had a clinical picture consistent with 
septic shock in the absence of evidence of bacterial coinfection, which has been reported as 
a rare outcome of CHIKV infection [4, 24]. Taken together, these findings suggested a rare 
but important role for CHIKV in fatal outcome. Histologic examination of tissue specimens 
from fatal cases therefore assisted in elucidating the pathophysiology of CHIKV infection in 
patients with severe disease.
COMPARATIVE DATA
Epidemiologic patterns detected through the PCSS, SEDSS, and EFASS were all in 
agreement regarding temporal trends of the chikungunya epidemic in Puerto Rico; however, 
each system provided a unique perspective of its magnitude and patients’ clinical course. 
Comparison of the incidence of cases detected through the SEDSS, which operated in just 2 
of 62 hospitals in Puerto Rico and does not include cases seen at outpatient clinics or private 
physicians’ offices, suggested a burden of clinically apparent chikungunya larger than was 
captured through passive surveillance. Such enhanced surveillance systems are therefore 
necessary to more accurately quantitate the burden of chikungunya, dengue, and other AFIs 
[25, 26]. Also, all surveillance systems demonstrated circulation of CHIKV for several 
months after the peak of the epidemic. How long CHIKV circulation will continue in Puerto 
Rico is unclear.
Collecting similar clinical data via all 4 surveillance systems enabled indirect comparison of 
the clinical signs and symptoms associated with chikungunya (Table 1). In agreement with 
the expected manifestations of CHIKV infection, fever and arthralgia were reported in the 
large majority (≥90% and ≥70%, respectively) of patients. Although these characteristic 
manifestations of chikungunya were not identified in all cases of chikungunya with positive 
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results of laboratory tests, their absence may be attributable to lack of collection or reporting 
of such manifestations, preverbal status (as among infants) and hence an inability to report 
subjective symptoms, and/or a variable spectrum of disease. Also, all surveillance systems 
that captured hospitalization status identified a similar rate of hospitalization among 
symptomatically infected individuals (approximately 10%). Severe manifestations were 
rarely documented (<1% of cases) in all surveillance systems, and even more rare was death 
in association with CHIKV infection (≤0.1% of cases). Of those patients who died while 
infected with CHIKV, death may more likely have been a result of exacerbation of 
preexisting medical conditions.
Use of various surveillance systems permitted 2 additional observations on dengue incidence 
during the first year of CHIKV circulation. First, dengue incidence had been steadily 
decreasing for several months before the introduction of CHIKV, suggesting that the low 
incidence of dengue during the chikungunya epidemic may have been attributable to natural 
decline due to high herd immunity following dengue epidemics in 2010 and 2012–2013. 
Second, both passive and enhanced surveillance demonstrated that, although dengue 
incidence was at a historic low, DENV was still circulating during the chikungunya 
epidemic.
CONCLUSIONS
Any single approach to chikungunya surveillance is unable to capture all clinical outcomes 
and epidemiologic characteristics of interest; however, all of the approaches described herein 
are associated with both strengths and weaknesses, which public health organizations 
seeking to characterize the burden of chikungunya and other emerging infectious diseases 
should consider with respect to their surveillance objectives. Passive surveillance is likely 
the most feasible approach to define temporal and geographic trends but is subject to 
inherent underreporting and unclear biases in case detection, both of which may be difficult 
to accurately estimate. Community-based case detection can be used to identify deficiencies 
in healthcare-seeking behaviors, estimate infection rates, and, if conducted in an 
appropriately selected sample of the population, estimate the actual number of CHIKV 
infections that occurred during an outbreak. The clinical spectrum of disease and burden of 
clinically apparent cases can both be accurately estimated by conducting facility-based 
surveillance; however, such systems are resource intensive and necessitate both a well-
designed study protocol and the participation of multiple partners. Caution should be taken 
when interpreting the findings of facility-based surveillance, as results are biased toward 
cases that are clinically more severe (ie, those with illness severe enough to merit seeking 
medical care). Surveillance for fatal cases is similarly resource intensive and only detects an 
extreme outcome associated with CHIKV infection. Although autopsy is not always 
logistically possible or culturally acceptable, findings from surveillance for fatal cases can 
be used to better understand the pathophysiology of CHIKV infection in individuals with 
severe manifestations. In areas where conducting all or some combination of these 
surveillance systems is possible, determination of the rates of symptomatic infection, 
clinically apparent disease, hospitalization, severe manifestations, and death in association 
with CHIKV infection may be possible.
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Several questions remain regarding both the endemicity of CHIKV and the effect of CHIKV 
transmission on DENV circulation. Because CHIKV and DENV are from distinct viral 
families, antibodies directed against CHIKV neither neutralize DENV nor cross-react in 
serologic diagnostic tests and vice versa, suggesting that there should not be direct 
immunologic suppression of DENV circulation following CHIKV infection in humans. 
Therefore, whether infection with CHIKV may result in a decreased likelihood of infection 
with DENV, either in humans or mosquitoes, is unknown. Thus, continued surveillance for 
dengue and chikungunya will be conducted to detect CHIKV circulation in Puerto Rico and 
its potential effects on the concomitant incidence of dengue.
As with chikungunya, there will be also be a need for multifaceted surveillance during the 
emergence of pathogens for which questions remain regarding public health burden, medical 
complications, and/or severe manifestations of disease. Puerto Rico benefited from several 
preestablished surveillance systems that were able to be expeditiously modified to detect 
chikungunya cases, and similar approaches may be feasible in other settings. In many 
jurisdictions, passive surveillance will be the only approach available to monitor 
chikungunya and other emerging infectious diseases. However, region-specific differences in 
healthcare-seeking behaviors, clinical reporting practices, availability of laboratory 
diagnostic testing, and cocirculation of other pathogens that cause AFI are likely to affect 
trends in cases reported via passive surveillance. Nonetheless, passive surveillance remains 
the most practical and feasible approach to compare epidemiologic trends across regions 
affected by chikungunya and other emerging infectious diseases.
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Figure 1. 
Dengue and chikungunya cases detected through various surveillance systems, by month of 
illness onset, Puerto Rico, May 2012–April 2015. A, Cases of suspected dengue and 
chikungunya and cases with positive results of laboratory testing reported by passive 
surveillance to the Puerto Rico Department of Health. B, Cases of laboratory test–positive 
dengue and chikungunya detected through the Sentinel Enhanced Dengue Surveillance 
System. C, Fatal cases of dengue and chikungunya with positive results of laboratory testing 
detected through the Enhanced Fatal Acute Febrile Illness Surveillance System.
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Figure 2. 
Cases of suspected chikungunya reported to the Passive Chikungunya Surveillance System, 
by municipality, Puerto Rico, May 2014–April 2015.
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Table 1
Demographic Characteristics, Clinical Signs and Symptoms, and Outcomes of People or Patients With 
Evidence of Chikungunya Virus Infection, as Gathered by Multiple Surveillance Systems, Puerto Rico, May 
2014 – April 2015
Variable
Household
Investigations (n = 59)
Passive Chikungunya
Surveillance System (n = 
4399)
Sentinel Enhanced 
Dengue
Surveillance System (n 
= 1566)
Enhanced Fatal AFI
Surveillance System (n 
= 31)
Diagnostic methods
  RT-PCR 10 (17) 4397 (100) 1498 (96) 31 (100)
  MAC ELISA 52 (88) 2 (<0.1) 148 (9) 14 (45)
  Immunohistochemistry NT NT NT 11 (35)
Demographic characteristics
  Age 46 y (9 y–94 y) 38 y (0 d–101 y) 25 y (0 d–97 y) 61 y (6 d–85 y)
  Male sex 32 (54) 1876 (42.6)a 739 (47.2) 19 (61)
  Pregnantb 1 (2) 8 (0.2) 55 (4) 1 (3)
Comorbidities
  Diabetes 11 (19) NC 170 (11) 15 (48)
  Hypertension 22 (37) NC 286 (18) 16 (52)
  Obesity NC NC NC 14 (45)
  Asthma 11 (19) NC 234 (15) 4 (13)
  Joint disease/arthritis 15 (25) NC NC 4 (13)
  Lupus NC NC NC 2 (6)
  Heart disease 6 (10) NC 91 (6) 4 (13)
  Kidney disease NC NC 24 (2) 5 (16)
Signs and symptomsb
  Fever 55 (93) 712 (90) 1459 (99.6) 25 (81)
  Arthralgia 56 (95) 627 (79) 1294 (83) 19 (61)
  Myalgia 48 (81) 635 (80) 1263 (81) 15 (48)
  Headache 41 (69) 544 (68) 1120 (72) 8 (26)
  Eye pain 18 (31) 344 (43) 718 (46) 3 (10)
  Anorexia NC 157 (20) 888 (57) 11 (35)
  Lethargy NC 30 (4) 1270 (81) 19 (61)
  Nausea/vomiting 19 (32) 226 (28) 893 (57) 7 (26)
  Rash 32 (54) 327 (41) 970 (62) 12 (39)
  Arthritis 29 (42) 114 (14) 694 (44) 6 (19)
  Bleeding manifestations 7 (12) 220 (28) 632 (40) 11 (35)
    Minorc 7 (12) 214 (27) 102 (6.5) 11 (35)
    Majord 0 (0) 10 (1) 1 (<0.1) 2 (6)
  Severe manifestationse 0 (0) 29 (4) 46 (2.9) 14 (27)
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Variable
Household
Investigations (n = 59)
Passive Chikungunya
Surveillance System (n = 
4399)
Sentinel Enhanced 
Dengue
Surveillance System (n 
= 1566)
Enhanced Fatal AFI
Surveillance System (n 
= 31)
Clinical outcomesb
  Duration of illness, d 6 (2–21) NC NC 6 (1–28)
  Sought medical care 25 (63)f NA NA 24 (77)
    Hospitalized 3 (12)f 263 (12) 171 (10.9) 12 (39)
    Duration of
      hospitalization, d
7 (3–15)f NC … 2 (0–23)
    Admitted to ICU 0 (0) NC 8 (0.5) 8 (26)
  Death 0 (0) 7 (0.1) 2 (0.1) 27 (100)
Data are no. (%) of individuals or median value (range).
Abbreviations: AFI, acute febrile illness; ICU, intensive care unit; MAC ELISA, immunoglobulin M antibody capture enzyme-linked 
immunosorbent assay; NA, not applicable; NC, not captured; NT, none tested; RT-PCR, reverse transcription–polymerase chain reaction.
aSex was not provided for 472 cases (10.7%).
bCases detected by the Passive Chikungunya Surveillance System only include 795 for which clinical and demographic data were available or 2171 
cases for which status of hospitalization was reported. Cases detected by the Enhanced Fatal AFI Surveillance System only include 27 for which 
data from medical records or family interviews were available.
c
Petechiae, bleeding gums, epistaxis, unspecified mucosal bleeding, and hematuria.
d
Purpura/ecchymoses, melena, hematemesis, and vaginal bleeding.
eJaundice, convulsions, effusion, edema, encephalitis, and hepatomegaly.
f
Data exclude index case patients who were reported to the Puerto Rico Department of Health and associated with subsequently initiated household 
investigations.
J Infect Dis. Author manuscript; available in PMC 2017 December 15.
